Patents Assigned to Aventis Pasteur
-
Publication number: 20040223949Abstract: The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response.Type: ApplicationFiled: October 21, 2003Publication date: November 11, 2004Applicant: Sunnybrook and Women's College Health Sciences Center Aventis Pasteur, Ltd.Inventors: Igor Astsaturov, Teresa Petrella, Mark DeBenedette, Neil Berinstein, David E. Spaner
-
Patent number: 6811783Abstract: A protective immune response against Chlamydial infection is achieved by in vivo administration of an immunogenic composition comprising two vectors and a pharmaceutically-acceptable carrier therefor. One of the vectors comprises a first nucleotide sequence encoding a major outer membrane protein (MOMP) of a strain of Chlamydia, preferably C. pneumoniae, and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The other of the vectors comprises a second nucleotide sequence encoding a 76 kDa protein of a strain of Chlamydia, preferably C. pneumoniae, and a promoter sequence operatively coupled to the second nucleotide sequence for expression of the 76 kDa protein in the host. The protection efficiency which is achieved by the immunization procedure is enhanced over that attained with the individual vectors alone.Type: GrantFiled: September 7, 1999Date of Patent: November 2, 2004Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Pamela L. Dunn
-
Patent number: 6808713Abstract: The present invention provides a method of immunizing a host against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method involves nucleic acid immunization, including DNA immunization, and employs a vector containing a nucleotide sequence which encodes an ATP/ADP translocase of a strain of Chlamydia pneumoniae. The nucleotide sequence is operably linked to a promoter to effect expression of the ATP/ADP translocase in the host. The host may be a human host. Modifications are possible within the scope of this invention.Type: GrantFiled: October 16, 2001Date of Patent: October 26, 2004Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
-
Publication number: 20040197912Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: ApplicationFiled: July 1, 2003Publication date: October 7, 2004Applicant: Aventis Pasteur, Ltd.Inventors: Neil Berinstein, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan, Devender Singh-Sandhu, Raymond P. Oomen, Shi-Xian Cao
-
Publication number: 20040170646Abstract: The present invention relates to methods for producing ALVAC virus on avian embryonic stem cells and compositions comprising ALVAC virus made using such methods.Type: ApplicationFiled: December 12, 2003Publication date: September 2, 2004Applicant: Aventis Pasteur, Inc.Inventors: Veronique Barban, Luc Aujame
-
Publication number: 20040170638Abstract: The invention relates to conjugates derived from the reductive amination of the pneumococcus serotype 5 capsular polysaccharide. The conditions for reductive amination differ from conventional conditions in that they make it possible to avoid the appearance of an undesirable compound which harms the immunogenicity of the conjugates. In carbon NMR spectrum, this undesirable compound is characterized by a resonance signal between 13 and 14 ppm. The aminated polysaccharides used to produce the conjugates therefore have a carbon NMR spectrum lacking a resonance signal between 13 and 14 ppm. The invention offers two conditions for reductive amination. According to a first method, the reductive amination is carried out at a slightly acidic pH (4-6.5) for at the very most 4 hours. According to a second method, the polysaccharide is first of all reduced, then fragmented and, finally, subjected to a reductive amination per se, under conditions which may or may not be conventional.Type: ApplicationFiled: January 15, 2004Publication date: September 2, 2004Applicant: Aventis Pasteur, S.A.Inventors: Noelle Mistretta, Emilie Danve, Monique Moreau
-
Patent number: 6780421Abstract: An amphipathic compound including a sterol-derived lipophilic grouping bound to a cationic grouping for use as an adjuvant in the delivery of a vaccine composition. In a particular embodiment, the lipophilic grouping is a cholesterol derivative and the cationic grouping is a quaternary ammonium or a protonatable amine. A vaccine composition including one or more antigens with at least one amphipathic compound having a sterol-derived lipophilic grouping bound to a cationic grouping, is also disclosed.Type: GrantFiled: September 9, 1997Date of Patent: August 24, 2004Assignee: Aventis Pasteur SAInventors: Jean Haensler, Emmanuelle Trannoy, Jorge Ronco
-
Patent number: 6780407Abstract: Attenutated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: human tumor necrosis factor; nuclear phosphoprotein p53, wiltype or mutant; human melanoma-associated antigen; IL-2; IFN&ggr;; IL-4; GMCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.Type: GrantFiled: September 15, 2000Date of Patent: August 24, 2004Assignee: Aventis PasteurInventors: Enzo Paoletti, James Tartaglia, William I. Cox
-
Patent number: 6764682Abstract: Adjuvant compositions for modulating an immune response to an antigen administered to a host comprise a mineral salt adjuvant and at least one other adjuvant. The compositions provide an adjuvanting effect on an antigen which is greater than the adjuvanting effect attainable by one of the adjuvants alone. An antigen is covalently bonded to a glycolipid analog to provide a discrete molecule which exhibits an enhanced adjuvanting effect on the antigen which is greater than the adjuvanting effect attainable in the absence of such covalent bonding.Type: GrantFiled: June 16, 1994Date of Patent: July 20, 2004Assignee: Aventis Pasteur LimitedInventors: Ali Kandil, Olive A. James, Michel H. Klein, Pele Chong
-
Patent number: 6737067Abstract: The invention concerns a purified recombinant glycoprotein having the following properties: a) an adherence capacity to CD4; b) an affinity with a anti-gp120 antibody capable of neutralizing in vitro HIV cell infection; c) an affinity with an anti-gp41 antibody; d) a timeric form free from inter-chain disulphide bonds. The invention also concerns a vaccine comprising said purified glycoprotein and an adjuvant. The invention further concerns a method for obtaining said glycoprotein, which consists in expressing, by means of genetic recombining techniques, a glycoprotein corresponding to the properties a), b) and c) mentioned above; purifying it, and subjecting it to steps involving at least a reducing agent, an ionic detergent and/or a neutral detergent in conditions leading to a glycoprotein having said properties.Type: GrantFiled: April 18, 2001Date of Patent: May 18, 2004Assignee: Aventis Pasteur S.A.Inventor: Michel Chevalier
-
Publication number: 20040086525Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding full-length, 5′-truncated or 3′-truncated 76 kDa protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 76 kDa protein gene in the host. Modifications are possible within the scope of this invention.Type: ApplicationFiled: June 30, 2003Publication date: May 6, 2004Applicant: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
-
Patent number: 6693087Abstract: An isolated and purified nucleic acid molecule encoding a POMP91A protein of a strain of Chlamydia, is useful for nucleic acid immunization of a host, including a human host, against disease caused by infection by a strain of Chlamydia, particularly C. pneumoniae.Type: GrantFiled: August 20, 1999Date of Patent: February 17, 2004Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Pamela L. Dunn, Raymond P. Oomen
-
Patent number: 6686339Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a inclusion membrane protein C of a strain of Chlamydia pneumoniae and a promoter to effect expression of the inclusion membrane protein C gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: June 15, 2001Date of Patent: February 3, 2004Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Pamela L. Dunn, Raymond P. Oomen
-
Patent number: 6676949Abstract: A host is immunized against infection by a strain of Chlamydia by initial administration of an attenuated bacteria harbouring a nucleic acid encoding a Chlamydia protein followed by administration of a Chlamydia protein in ISCOMs. This procedure enables a high level of protection to be achieved.Type: GrantFiled: December 3, 1999Date of Patent: January 13, 2004Assignees: University of Manitoba, Aventis Pasteur LimitedInventors: Robert C. Brunham, Andrew D. Murdin
-
Patent number: 6677127Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: September 13, 1999Date of Patent: January 13, 2004Assignee: Aventis Pasteur LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Publication number: 20040002455Abstract: The present invention provides reagents and methods for producing and utilizing targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity of the host.Type: ApplicationFiled: January 29, 2003Publication date: January 1, 2004Applicants: Aventis Pasteur, Ltd., Aventis Pharmaceuticals, Inc.Inventors: Robert Adam Uger, Danielle Salha, Brian Barber, Clarence C. Morse, Yong Guo, Su Cheng
-
Patent number: 6664049Abstract: Method and device for cell lysis in which a liquid mixture of bateria or eukaryoptic cells and of a lysing agent is produced continuously, and this mixture is caused to flow immediately in a steady stream inside a tubing (7), the flow rate of this stream being adjusted as a function of the diameter and of the length of the tubing (7) so as to obtain a substantially homegenous cell lysate at the outlet (8) of the said tubing.Type: GrantFiled: March 21, 2001Date of Patent: December 16, 2003Assignee: Aventis Pasteur S.A.Inventor: Michel Chevalier
-
Patent number: 6660275Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a CPN100605 polypeptide of a strain of Chlamydia pneumoniae and a promoter to effect expression of the CPN100605 polypeptide in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: July 26, 1999Date of Patent: December 9, 2003Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Publication number: 20030225017Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding a membrane ATPase of a strain of Chlamydia pneumoniae and a promoters to effect expression of the membrane ATPase in the host. Modifications are possible within the scope of this invention.Type: ApplicationFiled: December 30, 2002Publication date: December 4, 2003Applicant: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
-
Publication number: 20030224004Abstract: The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method employs a vector containing a nucleotide sequence encoding a transmembrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the transmembrane protein gene product in the host. Modifications are possible within the scope of this invention.Type: ApplicationFiled: February 6, 2003Publication date: December 4, 2003Applicant: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn